Cardio3 BioSciences SA acquires OnCyte LLC from Celdara Medical LLC
Executive Summary
Cardio3 BioSciences SA (cell therapies) acquired OnCyte LLC (immuno-oncology) from Celdara Medical LLC for $182mm including earn-outs. Cardio3 paid $10mm up front ($6mm in cash and $4mm in stock) along with developmental and sales milestones up to $172mm plus a tiered 5-8% sales royalty.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice